Overview

A Phase 1/2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma

Status:
Not yet recruiting

Trial end date:
2027-09-30

Target enrollment:

Participant gender:

Summary

To find a recommended dose of valemetostat that can be given in combination with rituximab and lenalidomide to patients with follicular lymphoma. The safety and effects of this drug combination will also be studied

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

M.D. Anderson Cancer Center

Collaborator:

Daiichi Sankyo, Inc.

Treatments:

Lenalidomide
Rituximab